Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor.
To assess the management of symptomatic leiomyomas using a nonsteroidal aromatase inhibitor in perimenopausal women. Case report. Academic clinical practice. A 53-year-old woman suffering from recurrent urinary retention secondary to a uterine leiomyoma. Fadrozole, orally, 2 mg daily for 8 weeks and then 1 mg daily for 4 weeks. Measurements of leiomyoma volume, and levels of serum E(2), LH, and FSH. Urinary retention resolved after 2 weeks of treatment and did not recur. Leiomyoma volume estimated by ultrasonography revealed a 71% reduction after 8 weeks of treatment. Fadrozole was useful for the management of a symptomatic leiomyoma without transient deterioration of symptoms. Clinical trials are warranted.